Compare Biogen Inc (BIIB) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Invesco Ltd. — how do they compare? Biogen Inc trades at $190.29 (market cap $28.34B), while Invesco Ltd. trades at $30.22 (market cap $12.74B). The key difference: Biogen Inc is far larger — about 2.2× Invesco Ltd.'s market cap, and Invesco Ltd. pays a 2.99% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | IVZ | |
|---|---|---|
Market Cap | $28.34B | $12.74B |
Sector | Health | Financials |
52-Week High | $216.63 | $29.44 |
52-Week Low | $122.68 | $16.74 |
Enterprise Value | $30.62B | $22.98B |
Dividend Yield | — | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Invesco (IVZ) trades at $28.4, down 2.0% on the day, with a bullish technical signal driven by moving averages. The company reported mixed earnings, beating in Q3 and Q4 2025 but missing in Q1 2026, while revenue grew to $6.38B in 2025. Analyst consensus is a Buy with a $30.50 price target, and recent news highlights upgrades and strong momentum.
The outlook is cautiously optimistic given analyst support and improving cash flow, but risks include negative net income margins and competitive pressures in asset management. Upside hinges on earnings recovery and AUM growth, while macroeconomic volatility remains a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
